The DOI matches its Crossref record.
Clinical Trial Endpoints in Acute Kidney Injury
Open accessAbstract
The development and use of consensus criteria for acute kidney injury (AKI) diagnosis and the inclusion of recently identified markers of renal parenchymal damage as endpoints in clinical trials have improved the ability of physicians to compare the incidence and severity of AKI across patient populations, provided targets for testing new treatments, and may increase insight into the mechanisms of AKI. To date, these markers have not consistently translated into important clinical outcomes. Is that because these markers of renal injury/dysfunction are measurements of process of care (and not indicative of persistently impaired renal function), or is it because patients do actually recover from AKI? Physicians currently have limited ability to measure renal function reserve, and the ultimate consequence of a case of AKI on long-term morbidity remains unclear. There is little doubt that groups of patients who develop AKI have worse outcomes than groups of patients who do not, but investigators are now realizing the value of measuring clinically meaningful renal endpoints in all subjects enrolled in AKI clinical trials. Important examples of these outcomes include persistently impaired renal function, new hemodialysis, and death. We propose that these major adverse kidney events (MAKE) be included in all effectiveness clinical trials. Adaptation of the MAKE composite assessed 30, 60, or 90 days following AKI (i.e., MAKE30 or MAKE90) will improve our capacity to understand and treat AKI and may also provide a consensus composite to allow comparison of different interventions. Primary endpoints for phase I and II clinical trials, on the other hand, should continue to use continuous markers of renal injury/dysfunction as well as ‘hard' clinical outcomes in order to generate meaningful data with limited subject exposure to untested treatments. By doing so, investigators may assess safety without requiring large sample sizes, demonstrate treatment effect of an unknown therapeutic, and power subsequent studies. In contrast, phase III trials should include consensus AKI criteria and more important subsequent clinical outcomes, such as MAKE90, as primary endpoints.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Rangaswami, J., Bhalla, V., Blair, J. E. A., Chang, T. I., Costa, S., Lentine, K. L., Lerma, E. V., Mezue, K., Molitch, M., Mullens, W., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000664 · Cited by 1,409
Acute kidney injury following cardiac surgery: current understanding and future directions
O’Neal, J. B., Shaw, A. D., & Billings, F. T. (2016) · Critical Care · doi:10.1186/s13054-016-1352-z · Cited by 553
Self-citationMyles, P. S., Boney, O., Botti, M., Cyna, A. M., Gan, T. J., Jensen, M. P., Kehlet, H., Kurz, A., De Oliveira, G. S., Peyton, P., et al. (2018) · British Journal of Anaesthesia · doi:10.1016/j.bja.2017.12.037 · Cited by 340
Identification and validation of biomarkers of persistent acute kidney injury: the RUBY study
the RUBY Investigators, Hoste, E., Bihorac, A., Al-Khafaji, A., Ortega, L. M., Ostermann, M., Haase, M., Zacharowski, K., Wunderink, R., Heung, M., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-019-05919-0 · Cited by 255
Bridging translation for acute kidney injury with better preclinical modeling of human disease
Skrypnyk, N. I., Siskind, L. J., Faubel, S., & de Caestecker, M. P. (2016) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00552.2015 · Cited by 61
Metadata
- Authors
- Billings IV, F. T., & Shaw, A. D.
- Venue
- Nephron Clinical Practice
- Publisher
- S. Karger AG
- Published
- 2014-09-24
- Volume
- 127
- Issue
- 1-4
- Pages
- 89-93
- ISSN
- 1660-2110 (ISSN-L)
- OpenAlex
- W2060817703
- Cited by
- 190
- References
- 0
- FWCI
- 2.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical Trial Endpoints in Acute Kidney Injury. https://app.cochat.ai/papers/10.1159/000363725
- The paper
- Billings IV, F. T., & Shaw, A. D. (2014). Clinical Trial Endpoints in Acute Kidney Injury. Nephron Clinical Practice. https://doi.org/10.1159/000363725
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.